Interferon-alpha is effective in HTLV-I-associated myelopathy: A multicenter, randomized, double-blind, controlled trial

被引:121
作者
Izumo, S
Goto, I
Itoyama, Y
Okajima, T
Watanabe, S
Kuroda, Y
Araki, S
Mori, M
Nagataki, S
Matsukura, S
Akamine, T
Nakagawa, M
Yamamoto, I
Osame, M
机构
[1] KYUSHU UNIV,NEUROL INST,DEPT NEUROL,FUKUOKA 812,JAPAN
[2] OITA MED UNIV,DEPT INTERNAL MED 3,OITA,JAPAN
[3] KARATSU RED CROSS HOSP,DEPT INTERNAL MED,KARATSU,JAPAN
[4] SAGA MED SCH,DEPT INTERNAL MED,SAGA,JAPAN
[5] KUMAMOTO UNIV,SCH MED,DEPT INTERNAL MED 1,KUMAMOTO 860,JAPAN
[6] NAGASAKI CHUO NATL HOSP,DEPT NEUROL,NAGASAKI,JAPAN
[7] NAGASAKI UNIV,SCH MED,DEPT INTERN MED 1,NAGASAKI,JAPAN
[8] MIYAZAKI MED COLL,DEPT INTERNAL MED 3,MIYAZAKI,JAPAN
[9] MIYAZAKI PREFECTURAL HOSP,DEPT NEUROL,MIYAZAKI,JAPAN
[10] OKAYAMA UNIV,FAC PHARMACEUT SCI,OKAYAMA,JAPAN
[11] NATL SANATORIUM OKINAWA HOSP,DEPT NEUROL,OKINAWA,JAPAN
关键词
D O I
10.1212/WNL.46.4.1016
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
A double-blind, multi-center study was performed on patients with HTLV-I-associated myelopathy (HAM) to evaluate the therapeutic effect of treatment with natural interferon-alpha (HLBI). Forty-eight HAM patients were enrolled and treated with either 0.3 MU (n = 15), 1.0 MU (n = 17), or 3.0 MU (n = 16) of HLBI for 28 days. Clinical evaluation included motor dysfunction, urinary disturbances, and changes of neurologic signs. The frequency of therapeutic response judged as excellent to good 4 weeks after starting therapy and 4 weeks after completion of therapy were 7.1% (1 of 14) and 8.3% (1 of 12) in the 0.3-MU group, 23.5% (4 of 17) and 26.7% (4 of 15) for the 1.0-MU group, and 66.7% (10 of 15) and 61.5% (8 of 13) for the 3.0-MU group. The therapeutic benefit in the 3.0-MU group was significantly higher than in the 0.3-MU group. There was no significant difference in the incidence of symptomatic side effects between groups. Abnormal laboratory data were obtained for some patients in the 1.0-MU and 3.0-MU groups; however, the treatment schedule could be continued in most patients. These results suggest that HAM patients may be safely treated with HLBI 3.0 MU every day for 4 weeks with favorable clinical effects.
引用
收藏
页码:1016 / 1021
页数:6
相关论文
共 26 条
[1]   SUPPRESSION OF HIV P24-ANTIGEN AND INDUCTION OF HIV ANTI-P24 ANTIBODY BY ALPHA-INTERFERON IN PATIENTS WITH CHRONIC HEPATITIS-B [J].
BROOK, MG ;
GOR, D ;
FORSTER, SM ;
HARRIS, W ;
JEFFRIES, DJ ;
THOMAS, HC .
AIDS, 1988, 2 (05) :391-393
[2]   CELL-SURFACE PHENOTYPE OF INVITRO PROLIFERATING LYMPHOCYTES IN HTLV-I-ASSOCIATED MYELOPATHY (HAM TSP) [J].
EIRAKU, N ;
IJICHI, S ;
YASHIKI, S ;
OSAME, M ;
SONODA, S .
JOURNAL OF NEUROIMMUNOLOGY, 1992, 37 (03) :223-228
[3]  
GESSAIN A, 1985, LANCET, V2, P407
[4]  
ICHIMARU M, 1988, JPN J CANC CHEMOTHER, V15, P2975
[5]   INVITRO MODULATION OF LYMPHOCYTE-PROLIFERATION BY PREDNISOLONE AND INTERFERON-ALPHA IN PATIENTS WITH HTLV-I-ASSOCIATED MYELOPATHY (HAM) [J].
IJICHI, S ;
EIRAKU, N ;
OSAME, M ;
IZUMO, S ;
KUBOTA, R ;
MARUYAMA, I ;
MATSUMOTO, M ;
SONODA, S .
JOURNAL OF NEUROIMMUNOLOGY, 1989, 23 (02) :175-178
[6]   ACTIVATED LYMPHOCYTES-T IN CEREBROSPINAL-FLUID OF PATIENTS WITH HTLV-I-ASSOCIATED MYELOPATHY (HAM TSP) [J].
IJICHI, S ;
EIRAKU, N ;
OSAME, M ;
IZUMO, S ;
KUBOTA, R ;
MARUYAMA, I ;
MATSUMOTO, M ;
NIIMURA, T ;
SONODA, S .
JOURNAL OF NEUROIMMUNOLOGY, 1989, 25 (2-3) :251-254
[7]   SPONTANEOUS PROLIFERATION OF PERIPHERAL-BLOOD LYMPHOCYTES INCREASED IN PATIENTS WITH HTLV-I-ASSOCIATED MYELOPATHY [J].
ITOYAMA, Y ;
MINATO, S ;
KIRA, J ;
GOTO, I ;
SATO, H ;
OKOCHI, K ;
YAMAMOTO, N .
NEUROLOGY, 1988, 38 (08) :1302-1307
[8]   ALTERED SUBSETS OF PERIPHERAL-BLOOD LYMPHOCYTES IN PATIENTS WITH HTLV-I ASSOCIATED MYELOPATHY (HAM) [J].
ITOYAMA, Y ;
MINATO, S ;
KIRA, J ;
GOTO, I ;
SATO, H ;
OKOCHI, K ;
YAMAMOTO, N .
NEUROLOGY, 1988, 38 (05) :816-818
[9]  
Izumo S., 1988, NEUROLOGY S, V39, P242
[10]   SYSTEMIC ALPHA-INTERFERON THERAPY OF MULTIPLE-SCLEROSIS [J].
KNOBLER, RL ;
PANITCH, HS ;
BRAHENY, SL ;
SIPE, JC ;
RICE, GPA ;
HUDDLESTONE, JR ;
FRANCIS, GS ;
HOOPER, CJ ;
KAMINLEWIS, RM ;
JOHNSON, KP ;
OLDSTONE, MBA ;
MERIGAN, TC .
NEUROLOGY, 1984, 34 (10) :1273-1279